Commentary/Editorials

Repurposing infectious disease vaccines for intratumoral immunotherapy
Ignacio Melero, Maria Gato, Tala Shekarian, Angela Aznar, Sandrine Valsesia-Wittmann, Christophe Caux, Iñaki Etxeberrria, Alvaro Teijeira, Aurelien Marabelle

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000443; DOI: 10.1136/jitc-2019-000443
Immunogenicity of cell death driven by immune effectors
Lorenzo Galluzzi, Giulia Petroni, Guido Kroemer

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000802; DOI: 10.1136/jitc-2020-000802
COVID-19 and immune checkpoint inhibitors: initial considerations
Ryan J Sullivan, Douglas B Johnson, Brian I Rini, Tomas G Neilan, Christine M Lovly, Javid J Moslehi, Kerry L Reynolds

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000933; DOI: 10.1136/jitc-2020-000933
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Alfredo Addeo, Michel Obeid, Alex Friedlaender

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000892; DOI: 10.1136/jitc-2020-000892
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Delia Dima, Dana Tomescu, Ecaterina Scarlatescu, Alina Tanase, Olafur Eysteinn Sigurjonsson, Anca Colita, Hermann Einsele, Ciprian Tomuleasa

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000742; DOI: 10.1136/jitc-2020-000742
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, Alexander Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John Thompson, Michel Obeid

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000604; DOI: 10.1136/jitc-2020-000604
Influence of gut microbiome on multiple myeloma: friend or foe?
Nausheen Ahmed, Mahmoud Ghannoum, Molly Gallogly, Marcos de Lima, Ehsan Malek

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000576; DOI: 10.1136/jitc-2020-000576
Moving cancer immunotherapy forward through the Journal for ImmunoTherapy of Cancer (JITC)
Pedro Romero

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000001; DOI: 10.1136/jitc-2019-000001
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
Esther Lutgens, Tom T.P. Seijkens

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000300; DOI: 10.1136/jitc-2019-000300
Management of hepatitis B in the era of checkpoint inhibition
Janice Dutcher

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000276; DOI: 10.1136/jitc-2019-000276

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages